Compare Eli Lilly And Co (LLY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vale SA — how do they compare? Eli Lilly And Co trades at $1,225.97 (market cap $1.08T), while Vale SA trades at $14.49 (market cap $61.97B). The key difference: Eli Lilly And Co is far larger — about 17.4× Vale SA's market cap, and Vale SA pays the higher dividend (8.35%). Which is the better fit depends on your goals.
| LLY | VALE | |
|---|---|---|
Market Cap | $1.08T | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $1.24K | $17.82 |
52-Week Low | $639.43 | $9.71 |
Enterprise Value | $1.13T | $78.22B |
Dividend Yield | 0.57% | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Vale S.A. (VALE) trades at $14.89, up 1.22% today, with a neutral technical stance. The company reported Q2 2026 EPS of $0.36, missing estimates of $0.41, continuing a trend of earnings misses. Revenue for 2025 was $38.40B, with net income margin at 5.11%. Cash flow from operations remains strong at $8.80B for 2025, supporting a $0.40 dividend scheduled for payment in September 2026.
The outlook is mixed: analyst consensus price target is $16.79 (12.8% upside), but rising costs and earnings misses pose risks. Base metals growth offers opportunity, yet iron ore volatility and debt increases require monitoring. The stock presents value with a P/E of 28.64 and EV/EBITDA of 7.65, but investor caution is warranted given recent performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
